$TDOC
Teladoc Health, Inc.

2023 Q3 Form 10-Q Financial Statement

#000147744923000012 Filed on July 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $660.2M $652.4M $637.7M
YoY Change 7.99% 10.13% 15.06%
Cost Of Revenue $186.0M $190.5M $188.9M
YoY Change 0.21% 4.42% 7.94%
Gross Profit $474.3M $461.9M $448.8M
YoY Change 11.39% 12.68% 18.35%
Gross Profit Margin 71.84% 70.79% 70.38%
Selling, General & Admin $168.0M $179.4M $324.2M
YoY Change -51.45% 6.26% 11.45%
% of Gross Profit 35.43% 38.84% 72.24%
Research & Development $84.29M $87.31M $77.58M
YoY Change -4.02% 8.02% 6.46%
% of Gross Profit 17.77% 18.9% 17.28%
Depreciation & Amortization $94.30M $75.47M $76.39M
YoY Change 50.39% 25.59% 45.97%
% of Gross Profit 19.88% 16.34% 17.02%
Operating Expenses $252.3M $266.7M $477.5M
YoY Change -49.12% 6.83% 14.76%
Operating Profit -$64.73M -$71.65M -$28.70M
YoY Change -7.72% -97.69% -22.16%
Interest Expense $5.646M $5.835M $1.893M
YoY Change -519.47% -234.54% -110.03%
% of Operating Profit
Other Income/Expense, Net -$1.792M -$207.0K $1.748M
YoY Change 14.07% -88.24% -531.6%
Pretax Income -$59.56M -$66.13M -$3.812B
YoY Change -20.22% -97.87% 6177.23%
Income Tax -$2.484M -$952.0K -$1.841M
% Of Pretax Income
Net Earnings -$57.07M -$65.18M -$3.810B
YoY Change -22.32% -97.9% 34584.31%
Net Earnings / Revenue -8.64% -9.99% -597.46%
Basic Earnings Per Share -$0.35 -$0.40
Diluted Earnings Per Share -$0.35 -$0.40 -$23.49
COMMON SHARES
Basic Shares Outstanding 165.0M shares 163.7M 161.9M
Diluted Shares Outstanding 165.1M shares 164.2M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.031B $958.7M $918.2M
YoY Change 14.6% 8.49% 2.48%
Cash & Equivalents $1.031B $958.7M $918.2M
Short-Term Investments $0.00
Other Short-Term Assets $8.307M $8.368M $12.10M
YoY Change -93.45% 19.39% 113.85%
Inventory $35.92M $34.05M $56.34M
Prepaid Expenses $62.25M $62.10M $63.16M
Receivables $205.9M $215.2M $210.6M
Other Receivables $12.88M $12.26M $25.09M
Total Short-Term Assets $1.387B $1.321B $1.315B
YoY Change 7.73% 5.07% 7.34%
LONG-TERM ASSETS
Property, Plant & Equipment $32.89M $30.39M $29.64M
YoY Change -54.61% 10.91% 8.84%
Goodwill $1.073B $1.073B $1.073B
YoY Change -77.85% -77.91% -92.6%
Intangibles $1.728B $1.784B $1.837B
YoY Change -6.79% -4.7% -3.85%
Long-Term Investments
YoY Change
Other Assets $74.45M $72.93M $48.54M
YoY Change 70.54% 92.22% 134.46%
Total Long-Term Assets $2.941B $2.995B $3.030B
YoY Change -56.86% -56.24% -81.65%
TOTAL ASSETS
Total Short-Term Assets $1.387B $1.321B $1.315B
Total Long-Term Assets $2.941B $2.995B $3.030B
Total Assets $4.328B $4.316B $4.345B
YoY Change -46.59% -46.73% -75.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.00M $16.07M $47.69M
YoY Change -63.27% -82.97% 0.92%
Accrued Expenses $225.0M $208.1M $193.4M
YoY Change -6.38% 47.64% 19.4%
Deferred Revenue $99.19M $107.4M $101.8M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $11.38M
YoY Change
Total Short-Term Liabilities $402.6M $383.4M $399.8M
YoY Change -2.13% 3.21% 20.77%
LONG-TERM LIABILITIES
Long-Term Debt $1.538B $1.537B $1.543B
YoY Change -0.28% -0.29% 24.97%
Other Long-Term Liabilities $1.693M $1.740M $1.618M
YoY Change -96.31% 8.14% 8.45%
Total Long-Term Liabilities $1.693M $1.740M $1.618M
YoY Change -99.89% 8.14% 8.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $402.6M $383.4M $399.8M
Total Long-Term Liabilities $1.693M $1.740M $1.618M
Total Liabilities $404.3M $385.1M $401.4M
YoY Change -80.29% 3.23% 20.72%
SHAREHOLDERS EQUITY
Retained Earnings -$15.20B -$15.14B -$15.01B
YoY Change 35.73% 36.12% 955.84%
Common Stock $17.54B $17.48B $17.36B
YoY Change 1.36% 1.38% -0.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.294B $2.295B $2.308B
YoY Change
Total Liabilities & Shareholders Equity $4.328B $4.316B $4.345B
YoY Change -46.59% -46.73% -75.5%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income -$57.07M -$65.18M -$3.810B
YoY Change -22.32% -97.9% 34584.31%
Depreciation, Depletion And Amortization $94.30M $75.47M $76.39M
YoY Change 50.39% 25.59% 45.97%
Cash From Operating Activities $105.6M $101.2M $65.55M
YoY Change 67.56% 9.42% -21.22%
INVESTING ACTIVITIES
Capital Expenditures $37.60M $36.57M $53.89M
YoY Change -187.03% -181.56% -335.12%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$37.60M -$36.57M -$53.89M
YoY Change -9.28% -18.44% 168.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000M 4.208M 4.381M
YoY Change 688.64% -415.44% -33.87%
NET CHANGE
Cash From Operating Activities 105.6M 101.2M 65.55M
Cash From Investing Activities -37.60M -36.57M -53.89M
Cash From Financing Activities 5.000M 4.208M 4.381M
Net Change In Cash 73.00M 68.82M 16.04M
YoY Change 228.73% 48.65% -77.01%
FREE CASH FLOW
Cash From Operating Activities $105.6M $101.2M $65.55M
Capital Expenditures $37.60M $36.57M $53.89M
Free Cash Flow $68.00M $64.61M $11.66M
YoY Change -35.99% -52.94% -89.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20230630#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20230630#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20230630#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
190540000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
182470000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
380647000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
369495000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
164171372 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
164171372 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161002075 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161002075 shares
CY2023Q2 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5790000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
60707000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2217000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65177000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2295144000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
677000 usd
tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5790000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
111341000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3996000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134405000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2295144000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1395000 usd
CY2022Q2 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4225000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7000 usd
CY2022Q2 tdoc Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Extinguishment
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtExtinguishment
2000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4980000 usd
tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4225000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7000 usd
tdoc Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Extinguishment
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtExtinguishment
2000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
120279000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-23579000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9775984000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
6084650000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134405000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9775984000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
145248000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
118304000 usd
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
1324000 usd
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
1486000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5778000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
6540000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3048000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5857000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
101763000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
111436000 usd
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-3557000 usd
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-2528000 usd
tdoc Accretion Of Interest
AccretionOfInterest
1693000 usd
tdoc Accretion Of Interest
AccretionOfInterest
1659000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4570000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7032000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
43948000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16625000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20195000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-20613000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-11974000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
17463000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
17453000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-31788000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
47417000 usd
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
20742000 usd
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
20712000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-15532000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-38328000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7546000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
10823000 usd
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4946000 usd
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-7266000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
111000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
216000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
114338000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
60722000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4267000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6455000 usd
us-gaap Payments For Software
PaymentsForSoftware
77927000 usd
us-gaap Payments For Software
PaymentsForSoftware
69213000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3264000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-82194000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72404000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
677000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4980000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
5435000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1972000 usd
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
1450000 usd
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
54000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-5524000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7561000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1482000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
39705000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10200000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
808000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2119000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
918182000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
893480000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
958695000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
881161000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
785000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
564000 usd
us-gaap Interest Paid
InterestPaid
8676000 usd
us-gaap Interest Paid
InterestPaid
8673000 usd
us-gaap Nature Of Operations
NatureOfOperations
Organization and Description of Business<div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care focusing on forging a new healthcare experience with better convenience, outcomes, and value around the world. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York.</span></div>
tdoc Number Of Professional Associations Consolidated As Variable Interest Entities
NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities
2 professional_association
tdoc Number Of Professional Corporations Consolidated As Variable Interest Entities
NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities
10 professional_corporation
us-gaap Use Of Estimates
UseOfEstimates
<div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Condensed Consolidated Statements of Operations; if material, the effects of changes in estimates are disclosed in the Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions by management affect areas including the value and useful life of long-lived assets (including intangible assets), the value of goodwill, the capitalization and amortization of software development costs, deferred device and contract costs, allowances for sales and for doubtful accounts, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees), the accounting for income taxes, contingencies, litigation and related legal accruals, the accounting for stock-based compensation awards, and other items as described in the Summary of Significant Accounting policies in this Quarterly Report and in the 2022 Form 10-K.</span></div>
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
652406000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
592379000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1281650000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1157729000 usd
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
121600000 usd
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
109600000 usd
tdoc Contract With Customer Liability Period Increase Decrease
ContractWithCustomerLiabilityPeriodIncreaseDecrease
7800000 usd
tdoc Contract With Customer Liability Period Increase Decrease
ContractWithCustomerLiabilityPeriodIncreaseDecrease
7500000 usd
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-70300000 usd
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-58000000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-76800000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-60200000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
86400000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
26700000 usd
CY2023Q2 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
30300000 usd
CY2022Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
29956000 usd
CY2023Q2 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
18234000 usd
CY2022Q4 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
8404000 usd
CY2023Q2 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
48534000 usd
CY2022Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
38360000 usd
CY2022Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
38360000 usd
tdoc Deferred Device Cost And Other Additions
DeferredDeviceCostAndOtherAdditions
32841000 usd
tdoc Deferred Device Cost And Other Cost Of Revenue Recognized
DeferredDeviceCostAndOtherCostOfRevenueRecognized
22667000 usd
CY2023Q2 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
48534000 usd
CY2023Q2 tdoc Inventory Raw Materials And Purchased Parts Gross
InventoryRawMaterialsAndPurchasedPartsGross
23424000 usd
CY2022Q4 tdoc Inventory Raw Materials And Purchased Parts Gross
InventoryRawMaterialsAndPurchasedPartsGross
30126000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
939000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
433000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
17918000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
31977000 usd
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
8227000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
6194000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
34054000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
56342000 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
62103000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
63159000 usd
CY2023Q2 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
30300000 usd
CY2022Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
29956000 usd
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
12263000 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
25091000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
8368000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
12104000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
113034000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
130310000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
1073190000 usd
CY2023Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
13400000000 usd
CY2022Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
12300000000 usd
CY2022Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2505476000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
721371000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1784105000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2421251000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
584486000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1836765000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
72500000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
56700000 usd
CY2023Q2 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
19700000 usd
CY2022Q2 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
7000000 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
36300000 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
13700000 usd
CY2022Q4 tdoc Cloud Computing Costs Net
CloudComputingCostsNet
25400000 usd
tdoc Cloud Computing Expense
CloudComputingExpense
500000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
16901000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10152000 usd
CY2023Q2 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
15953000 usd
CY2022Q4 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
16407000 usd
CY2023Q2 tdoc Performance Guarantees And Accrued Rebates Current
PerformanceGuaranteesAndAccruedRebatesCurrent
31728000 usd
CY2022Q4 tdoc Performance Guarantees And Accrued Rebates Current
PerformanceGuaranteesAndAccruedRebatesCurrent
18687000 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
1465000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1480000 usd
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1176000 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3817000 usd
CY2023Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
4178000 usd
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
5981000 usd
CY2023Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
5348000 usd
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
3247000 usd
CY2023Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
43904000 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
35055000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11919000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13592000 usd
CY2023Q2 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
15067000 usd
CY2022Q4 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
10183000 usd
CY2022Q4 tdoc Other Current Liabilities Staff Augmentation
OtherCurrentLiabilitiesStaffAugmentation
3391000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
46701000 usd
CY2022Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
168693000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7943000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11967000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9350000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8156000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6044000 usd
CY2023Q2 tdoc Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
14753000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
58213000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9485000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
48728000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11919000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36809000 usd
CY2023Q2 us-gaap Restructuring Costs
RestructuringCosts
7500000 usd
us-gaap Restructuring Costs
RestructuringCosts
15600000 usd
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
4043000 usd
us-gaap Restructuring Charges
RestructuringCharges
10769000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
7984000 usd
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
6828000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
14194292 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4243934 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.79
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
59679 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.37
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
78033 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1402000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
89504 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
49.26
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4136076 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M20D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21701000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4136076 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y7M20D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
21701000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3047326 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y5M12D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21634000 usd
CY2023Q2 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
600000 usd
CY2022Q2 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
23000000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6558
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.6792
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0368
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0408
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55725000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
101763000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
111436000 usd
tdoc Share Based Payment Arrangement Expense Reversal Due To Restructuring
ShareBasedPaymentArrangementExpenseReversalDueToRestructuring
4500000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1200000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
652406000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
592379000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1281650000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1157729000 usd
CY2023Q2 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
72155000 usd
CY2022Q2 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
46711000 usd
tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
124920000 usd
tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
101208000 usd
CY2023Q2 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
72155000 usd
CY2022Q2 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
46711000 usd
tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
124920000 usd
tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
101208000 usd
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3030000000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
11558000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1225000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
20469000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1389000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
5835000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
5562000 usd
us-gaap Interest Expense
InterestExpense
11098000 usd
us-gaap Interest Expense
InterestExpense
11206000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-207000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1760000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4700000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1036000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
75465000 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59371000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
145248000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
118304000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
55725000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
51000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
101763000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
111436000 usd
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5080000 usd
CY2022Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2892000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
11024000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
7399000 usd
CY2023Q2 us-gaap Restructuring Costs
RestructuringCosts
7530000 usd
CY2022Q2 us-gaap Restructuring Costs
RestructuringCosts
0 usd
us-gaap Restructuring Costs
RestructuringCosts
15632000 usd
us-gaap Restructuring Costs
RestructuringCosts
0 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66129000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3102649000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-134676000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9776784000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-952000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1188000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-271000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65177000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3101461000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134405000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9775984000 usd
CY2023Q2 us-gaap Noncurrent Assets
NoncurrentAssets
30392000 usd
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
29641000 usd
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001477449-23-000012-index-headers.html Edgar Link pending
0001477449-23-000012-index.html Edgar Link pending
0001477449-23-000012.txt Edgar Link pending
0001477449-23-000012-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tdoc-20230630.htm Edgar Link pending
tdoc-20230630.xsd Edgar Link pending
tdoc-20230630xexx102.htm Edgar Link pending
tdoc-20230630xexx103.htm Edgar Link pending
tdoc-20230630xexx104.htm Edgar Link pending
tdoc-20230630xexx105.htm Edgar Link pending
tdoc-20230630xexx108.htm Edgar Link pending
tdoc-20230630xexx109.htm Edgar Link pending
tdoc-20230630xexx311.htm Edgar Link pending
tdoc-20230630xexx312.htm Edgar Link pending
tdoc-20230630xexx321.htm Edgar Link pending
tdoc-20230630xexx322.htm Edgar Link pending
tdoc-20230630_def.xml Edgar Link unprocessable
tdoc-20230630_lab.xml Edgar Link unprocessable
tdoc-20230630_pre.xml Edgar Link unprocessable
tdoc-20230630_htm.xml Edgar Link completed
tdoc-20230630_cal.xml Edgar Link unprocessable